Idiopathic Pulmonary Fibrosis as a Challenge for the Polish Healthcare System
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2015, Vol 8, Issue 2
Abstract
Idiopathic pulmonary fibrosis (IPF) is a rare disease characterised by age-dependent incidence, unclear aetiology and progressive course. Given the complexity of the diagnostic pathway and limited therapeutic options, and according to the fact that the Polish society is ageing, healthcare and social security expenditure are considerable and likely to rise. Until recently, there was no effective treatment for patients with IPF. After diagnosis only procedures that relieve the symptoms of the disease and treat its complications or lung transplantation were offered. In recent years a huge interest in this clinical entity has been seen. This resulted in the introduction of new drugs, whose efficacy has been confirmed in reliable clinical trials and whose slow the progression of the disease and improve survival of patients. The first such drug was pirfenidone; however such treatment is not available in Poland. Furthermore, due to the inadequacy of Polish legislative reimbursement solutions, which do not take into account the specific nature of rare disease, there are not used any favourable solution during the assessment of public funding of orphan drugs. This is contrary to European consensuses on an egalitarian approach to the use of orphan drugs. It is necessary to develop standards of care for IPF patients, including systemic solutions and the inclusion of the drugs used in the treatment of IPF on the reimbursement list. In long term this will reduce the financial burden associated with the disease, and thus reduce the direct and indirect costs resulting from its prevalence.
Authors and Affiliations
Marcin Kwiecień, Monika Homa, Małgorzata Budasz-Świderska
Keywords
Related Articles
- EP ID EP180589
- DOI 10.7365/JHPOR.2015.2.1
- Views 79
- Downloads 0
European Union Legal System for Health Emergencies
Background- The aim is to analyze how the legal system in the European Union that deals with the public health emergencies in terms of organization and readiness to respond to public health emergencies. Methods - The m...
Approach to uncertainty in health technology assessment in a Central and Eastern European country: appraisal of cancer drugs by a Polish HTA agency in presence of high crossover rates in clinical trials
Background: Health technology assessment (HTA) plays an important role in reimbursement decision making in Poland and its principles are similar to those used in other countries. However, specific inter-country differenc...
Assessment of quality and clinical significance of endpoints in cancer immunotherapy
This review describes available immunotherapeutic agents approved for the treatment of prostate cancer (sipuleucel-T), advanced melanoma (ipilimumab, pembrolizumab, nivolumab) and NSCLC (nivoluamb) and underline that the...
Major Cardiovascular Consequences of Familial Hypercholesterolemia in Poland from the Economic Perspective
Background. Familial hypercholesterolemia (FH) is a genetic disease characterised by high LDL-C level with other lipid fractions levels typically correct. The disease involves the accelerated development of arteriosclero...
Assessment of thrombocytopenia symptoms using vignettes. Preliminary report on the development and implementation of a new instrument
Objective: Our aim was to create a vignette enabling the assessment of the impact of thrombocytopenia symptoms on patients’ quality of life. Methods: The vignettes which we created are focused on thrombocytopenia sym...